WallStreetZenWallStreetZen

NASDAQ: LABP
Landos Biopharma Inc Stock Forecast, Predictions & Price Target

Be the first to know when Wall Street analysts revise their LABP stock forecasts and price targets.

Forecast return on equity

Is LABP forecast to generate an efficient return?
Company
N/A
Industry
N/A
Market
34.96%

Forecast return on assets

Is LABP forecast to generate an efficient return on assets?
Company
N/A
Industry
N/A

LABP revenue forecast

What is LABP's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$600.0k
Avg 2 year Forecast
$18.2M
Avg 3 year Forecast
$97.8M

LABP vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
LABP$6.35N/AN/A
MTEM$3.68N/AN/A
MAIA$1.40N/AN/A
XLO$0.72N/AN/A
NTRB$2.51N/AN/A

Landos Biopharma Stock Forecast FAQ

What is LABP's revenue growth forecast for 2027-2029?

(NASDAQ: LABP) Landos Biopharma's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 45.76%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.79%.

Landos Biopharma's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast LABP's revenue for 2027 to be $1,870,037, with the lowest LABP revenue forecast at $1,870,037, and the highest LABP revenue forecast at $1,870,037. On average, 1 Wall Street analysts forecast LABP's revenue for 2028 to be $56,724,468, with the lowest LABP revenue forecast at $56,724,468, and the highest LABP revenue forecast at $56,724,468.

In 2029, LABP is forecast to generate $304,816,096 in revenue, with the lowest revenue forecast at $304,816,096 and the highest revenue forecast at $304,816,096.

If you're new to stock investing, here's how to buy Landos Biopharma stock.

What is LABP's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: LABP) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of N/A.

What is LABP's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: LABP) forecast ROE is N/A, which is considered weak.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.